Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Apple Restores Telegram to App Store After Content Policy Violation 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Fort Lauderdale, Fla., March 19, 2018 -- CTI Clinical Trial & Consulting Services (CTI), a full-service, contract research organization (CRO) specializing in Early Phase, rare disease clinical trials, has expanded its existing partnership with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of patient-centric, clinical data management technology. Under the terms of a new multi-year, multi-million dollar agreement, CTI will use TrialMaster electronic data capture (EDC) solutions for studies during a four-year period. CTI conducts a high volume of diverse, complex and technically challenging studies around the globe.
“We’re excited to continue building our partnership with OmniComm,” said Todd Bonta, director of Clinical Data Management at CTI. “We have had a history of success with OmniComm’s TrialMaster suite, and we look forward to continuing to offer our sponsors the unique benefits provided by OmniComm’s solutions.”
OmniComm was selected for the partnership based on its EDC solutions, which offer inherent flexibility and broad capabilities to support clinical studies across all phases of clinical development. Deploying studies in an efficient, timely and cost-effective manner was especially important to CTI. OmniComm’s robust, state-of-the art, compliant hosting environment was another critical factor in the selection process.
“OmniComm has been a valuable and flexible partner, helping CTI build a powerful suite of solutions for our Clinical Operations department,” said Louis Minham, senior director, Information Technologies at CTI. “We are happy to continue to partner with OmniComm as they expand their TrialMaster suite.”
Under the terms of the agreement, CTI will use TrialMaster, TriaIBuilder®, TriaIExplorer® AdHoc reporting, AutoEncoder®, OmniConnect, LabLoading and eLearning.
“Not only are we very proud of our established relationship with CTI, but also that we have earned their trust for increased business and commitment,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “It is a pleasure to work with a company that shares the same level of passion for problem solving for clients and seeks robust, scalable and innovative solutions to help meet expectations.”
About CTI Clinical Trial & Consulting Services
CTI Clinical Trial & Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization, including real world evidence. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hematology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across six continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in the Greater Cincinnati, OH area, with operations across North America, Europe, Latin America, and Asia-Pacific. Please visit http://ctifacts.com for more information.
About OmniComm Systems, Inc.
OmniComm Systems provides a critical role in enhancing patient lives by shortening time to market of
essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]
